Lesuride Injection, containing Levosulpiride 25 mg, is a prokinetic and antipsychotic agent primarily indicated for the treatment of gastrointestinal motility disorders and certain psychiatric conditions. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts its therapeutic effects by modulating dopaminergic transmission in the central nervous system and gastrointestinal tract. This action facilitates enhanced gastric emptying and intestinal motility, making Lesuride Injection effective in managing functional dyspepsia, gastroparesis, and irritable bowel syndrome with predominant symptoms of delayed gastric emptying. Additionally, its central dopaminergic antagonism contributes to its utility in treating schizophrenia, depression, and other neuropsychiatric disorders. Administered via intramuscular or intravenous injection, Lesuride Injection offers rapid onset of action, suitable for acute management or when oral administration is not feasible. The dosage and duration of therapy should be individualized based on clinical response and patient tolerance. Common adverse effects may include extrapyramidal symptoms, sedation, and gastrointestinal disturbances. Caution is advised in patients with a history of hypersensitivity to sulpiride or related compounds, and in those with renal or hepatic impairment. Lesuride Injection should be used under strict medical supervision, with regular monitoring for efficacy and potential side effects to ensure optimal therapeutic outcomes.